Author(s): Haas EJ, McLaughlin JM, Khan F, Angulo FJ, Anis E, Lipsitch M, Singer SR, Mircus G, Brooks N, Smaja M, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S|Journal: Lancet Infect Dis|PMID:34562375| September 2021
On Dec 20, 2020, Israel initiated a nationwide COVID-19 vaccination campaign for people aged 16 years and older and exclusively…
Author(s): Peak CM, Kahn R, Grad YH, Childs LM, Lipsitch M, Buckee CO|Journal: Lancet Infect Dis|PMID:32445710| May 2020
Voluntary individual quarantine and voluntary active monitoring of contacts are core disease control strategies for emerging infectious diseases such as…
Author(s): Lipsitch M, Waldor MK|Journal: Lancet Infect Dis|PMID:32618282| May 2020
A randomised controlled trialĀ found no significant benefit of lopinavir-ritonavir over placebo in patients with severe corona-virus disease 2019 (COVID-19). Even…
Author(s): Lewnard JA, Hanage WP|Journal: Lancet Infect Dis|PMID:30709666| February 2019
Serotype replacement in invasive pneumococcal disease threatens to undermine the most costly vaccination programme currently undertaken. However, the effects of…
Author(s): Leung K, Lipsitch M, Yuen KY, Wu JT|Journal: Lancet Infect Dis|PMID:27914853| March 2017
Antivirals (eg, oseltamivir) are important for mitigating influenza epidemics. In 2007, an oseltamivir-resistant influenza seasonal A H1N1 strain emerged and…